Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00711737

Enrollment

Registered

2008-07-09

Start date

2008-09-30

Completion date

2010-10-31

Last updated

2011-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder, Major Depression, Panic Disorder

Keywords

metabolic parameters, escitalopram, metabolic syndrome, antidepressant

Brief summary

The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

Detailed description

This is an open-label study, with 4 scheduled visits. Recruitment of 100 subjects. Assessments include demographics, diagnosis, smoking frequency, Clinical Global Scale (CGI-S), weight, height,blood pressure, waist and hip circumference and fasting blood glucose and lipd profile. Statistical analysis will be exploratory and mainly descriptive.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Give informed consent * Requires pharmacological treatment with escitalopram for major depression, generalized anxiety disorder or panic disorder * Aged 21 years old and above * Able to comprehend and comply with protocol * Not pregnant and if of child-bearing age, using adequate methods of contraception

Exclusion criteria

* Currently taking or has taken in previous 3 months, any other antidepressants, antipsychotics, mood stabilizers, weight loss or lipid-profile modifying drugs * Contraindications to escitalopram * Unstable medical illness and/or is already under treatment of diabetes, hypertension, dyslipidemia, ischemic heart disease * History of non-response to escitalopram * Meets IDF definition of metabolic syndrome * Significant risk of suicide * Primary diagnosis or comorbid diagnosis of psychotic disorder, bipolar disorder, substance dependence and/or dementia

Countries

Singapore

Outcome results